Fujifilm Holdings is the biotechnology company most prolific at making international expansions, followed by Danaher and Beijing BGI-GBI Biotech. GlobalData’s biotechnology foreign direct investment (FDI) company report highlights the current foreign investments made by leading biotechnology investors. Buy the report here.
Fujifilm Holdings has been the most active biotechnology greenfield investor between Q1 2019 and Q2 2024, according to GlobalData’s FDI Projects Database. The parent company has been actively investing through several of its subsidiaries/company divisions.
Smarter leaders trust GlobalData
Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.
The majority of Fujifilm Holdings investments were in the genomics subsector. In fact, 18.3% of its total foreign investments were in this subsector. It also created projects across a further 16 subsectors.
By business function, most (46.7%) of Fujifilm Holdings projects were related to manufacturing. R&D and Healthcare provision were the next most popular operations undertaken by Fujifilm Holdings.
The company has been active across six world regions, mainly focused on North America which received 35% of the company’s greenfield investments between Q1 2019 and Q2 2024. Its top three destination countries (by number of greenfield FDI projects) were the US, the UK and India. Combined these three countries account for 183.3% of its total number of biotechnology investments.
Fujifilm Holdings created more FDI projects in 2021 compared to any other year between Q1 2019 and Q2 2024.
Other leading FDI project generators in the biotechnology industry include Danaher, Beijing BGI-GBI Biotech, and F. Hoffmann-La Roche.
The US is the leading source market for outbound biotechnology greenfield FDI projects. The country accounts for 29% of total outbound biotechnology investment projects. There have been 101 unique parent companies from the US that have announced biotechnology FDI projects between between Q1 2019 and Q2 2024.
To further understand the top biotechnology FDI companies, access GlobalData’s Top biotechnology Foreign Direct Investment Companies report.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s FDI Projects Database records greenfield FDI throughout the world in real-time. The data can be used to analyse company cross-border expansion activities as well as identify industry, thematic and geographic trends.
